Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -23.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.70 | 9.76 | 6.84 | 4.89 | 3.06 | 2.34 | 4.87 | 5.37 | 5.12 | 3.30 | 2.99 | 2.22 | 1.25 | 1.58 | 1.28 | 1.63 | 1.41 | 1.60 | 1.85 | 2.74 | 2.87 |
| — | +318.0% | +40.5% | -9.0% | -40.2% | -29.2% | +63.1% | +141.8% | +309.1% | +109.2% | +132.7% | +36.3% | -11.3% | -1.6% | -30.5% | -40.6% | -50.7% | -54.7% | -64.7% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -34.2% | -12.2% | -9.7% | -9.3% | -7.1% | -7.1% | -9.2% | -8.4% | -6.8% | -6.0% | -6.7% | -9.9% | -8.5% | -6.7% | -6.8% | -5.5% | -5.8% | -6.3% | -5.5% | -4.5% | -4.4% |
| — | -71.8% | -5.2% | -11.1% | -3.8% | -17.7% | -37.4% | +15.4% | +20.1% | +10.1% | +1.2% | -80.5% | -48.4% | -5.7% | -23.3% | -20.9% | -29.4% | -84.7% | -9.8% | — | +67.3% | |
| ROA | -32.3% | -11.5% | -9.2% | -8.8% | -6.8% | -6.8% | -8.7% | -7.9% | -6.5% | -5.8% | -6.4% | -9.3% | -8.0% | -6.3% | -6.4% | -5.2% | -5.5% | -6.1% | -5.3% | -4.4% | -4.3% |
| — | -69.8% | -5.6% | -11.2% | -3.8% | -16.6% | -35.8% | +14.1% | +18.3% | +8.5% | +0.3% | -77.4% | -45.2% | -4.6% | -21.8% | -19.1% | -27.3% | -80.0% | -70.5% | +9.4% | — | |
| ROIC | -32.4% | -11.0% | -8.7% | -8.6% | -6.6% | -6.8% | -8.5% | -7.8% | -6.6% | -5.8% | -7.0% | -10.1% | -8.1% | -6.7% | -6.3% | -5.7% | -5.7% | -5.4% | -4.6% | -3.6% | -3.8% |
| — | -61.1% | -2.3% | -9.0% | +0.0% | -17.5% | -22.6% | +22.6% | +18.2% | +12.5% | -11.2% | -78.6% | -42.4% | -23.1% | -37.2% | -57.5% | -50.4% | -14.2% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | — | — |
| — | +8.0% | -27.5% | -25.9% | -17.6% | -24.0% | +8.1% | -39.3% | -52.3% | -46.1% | -42.8% | +33.6% | +158.5% | +156.5% | +103.2% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 19.85 | 16.24 | 22.61 | 19.85 | 26.51 | 28.87 | 20.99 | 19.93 | 26.35 | 30.24 | 37.08 | 19.50 | 18.23 | 22.01 | 26.22 | 21.53 | 27.82 | 27.49 | 26.85 | 26.97 | 33.50 |
| — | -43.8% | +7.7% | -0.4% | +0.6% | -4.5% | -43.4% | +2.2% | +44.5% | +37.4% | +41.4% | -9.4% | -34.5% | -19.9% | -2.4% | -20.2% | -16.9% | -38.9% | -58.1% | -9.7% | — | |
| Quick Ratio | 19.85 | 16.24 | 22.61 | 19.85 | 26.51 | 28.87 | 20.99 | 19.93 | 26.35 | 30.24 | 37.08 | 19.50 | 18.23 | 22.01 | 26.22 | 21.53 | 27.82 | 27.49 | 26.85 | 26.97 | 33.50 |
| — | -43.8% | +7.7% | -0.4% | +0.6% | -4.5% | -43.4% | +2.2% | +44.5% | +37.4% | +41.4% | -9.4% | -34.5% | -19.9% | -2.4% | -20.2% | -16.9% | -38.9% | -58.1% | -9.7% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EWTX stock.
Edgewise Therapeutics, Inc.'s current P/E is -24.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Edgewise Therapeutics, Inc.'s business trajectory between earnings reports.